MedPath

Phase I trial of Bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-small cell lung cancer

Phase 1
Conditions
Previously treated non-small cell lung cancer
Registration Number
JPRN-UMIN000008613
Lead Sponsor
Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

1)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 2)Patients with uncontrollable complications(e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea). 3)Patients with active severe infections. 4)History of active double cancer within 5 years prior to the study. 6)Patients with symptomatic brain metastasis 7) 8)History of hemoptysis with 2.5mL or more and Continued bloody phlegm. 9)Pregnancy or lactation 10)evidence of bleeding diathesis or coagulopathy 11)tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor 12)current or previous (within the last 1 year) history of GI perforation 13)current history of uncontrorable hypertension 14)Impossible cases with oral administration. 15)severe drug allergy for 5-FU or UFT or S-1 content medicine 16) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety
Secondary Outcome Measures
NameTimeMethod
Overall survival, objective response rate , progression free survival
© Copyright 2025. All Rights Reserved by MedPath